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Ambra1 is considered an autophagy and 
trafficking protein with roles in 
neurogenesis and cancer cell invasion. Here 
we report that Ambra1 also localises to the 
nucleus of cancer cells, where it has a novel 
nuclear scaffolding function that controls 
gene expression. Using biochemical 
fractionation and proteomics, we found that 
Ambra1 binds to multiple classes of 
proteins in the nucleus, including nuclear 
pore proteins, adaptor proteins such as 
FAK and Akap8, chromatin modifying 
proteins and transcriptional regulators like 
Brg1 and Atf2. We identified biologically-
important genes such as Angpt1, Tgfb2, 
Tgfb3, Itga8 and Itgb7 whose transcription 
is regulated by Ambra1-scaffolded 
complexes, likely by altering histone 
modifications and Atf2 activity. Therefore, 
in addition to its recognised roles in 
autophagy and trafficking, Ambra1 
scaffolds protein complexes at chromatin, 
regulating transcriptional signalling in the 
nucleus. This novel function for Ambra1, 
and the specific genes impacted, may help 
to explain the wider role of Ambra1 in 
cancer cell biology. 
 
INTRODUCTION 
Ambra1 (Activating Molecule in Beclin1-
Regulated Autophagy) is already known to 
be an important protein in physiology, e.g. 
in the development of the central nervous 
system, vertebrate embryogenesis, adult 
neurogenesis and cancer cell invasion (1-
5). However, the full range of functions of 
this crucial cellular regulator is not 
understood. As an important autophagy 
regulator, Ambra1 binds Beclin1 and is 
involved in the initiation of autophagy that 
is needed for neurogenesis (2). In the 
absence of autophagy, the Ambra1–
Beclin1–Vps34 complex is bound to the 
dynein motor complex; when autophagy is 
induced, the kinase ULK1 phosphorylates 
Ambra1, resulting in its release from the 
dynein complex (6,7). Additionally, the 
function of Ambra1 is negatively regulated 
by mTOR, which suppresses its binding to 
the E3-ligase TRAF1 and the 
ubiquitylation of ULK1, thereby 
controlling the stability and function of 
ULK1 (8). During apoptosis, caspases and 
calpains mediate cleavage as well as 
degradation of Ambra1 (9). Furthermore, 
Ambra1 expression is regulated by RNF2-
dependent ubiquitylation, resulting in 
degradation (10). Ambra1 is also involved 
in the regulation of mitophagy (11). 
Ambra1 has been both positively and 
negatively implicated in cancer. Thus far, it 
has been proposed as a tumour suppressor, 
supporting the binding of c-Myc to the 
phosphatase PP2A, resulting in c-Myc 
degradation, as well as reduced 
proliferation and tumourigenesis (12). 
Ambra1 has been positively implicated in 
cholangiocarcinoma, where overexpression 
is correlated with invasion and poor 
survival (5). In addition, through its ability 
to bind PP2A, Ambra1 stabilises the 
transcription factor FOXO3, triggering 
FOXP3-mediated transcription, and T-cell 
differentiation and homeostasis (13).  
We reported previously that in squamous 
cell carcinoma (SCC) cells derived from 
the mutated oncogenic H-Ras-driven 
DMBA/TPA model of carcinogenesis, 
Ambra1 is a Focal Adhesion Kinase 
(FAK)- and Src-binding partner, regulating 
cancer cell polarisation and chemotactic 
invasion (4,14). In FAK-depleted SCC 
cells, Ambra1 is involved in the targeting 
of active Src to intracellular autophagic 
puncta, while an Ambra1-binding-impaired 
FAK mutant retains more active FAK and 
Src at focal adhesions, resulting in 
increased cell adhesion and invasion. We 
concluded that Ambra1 lies at the heart of 
an intracellular trafficking network in SCC 
cells, regulating the localisation of active 
FAK and Src required for cancer processes 
(4).  
Here, we investigate a nuclear function of 
Ambra1, and show that it binds to FAK in 
the nucleus, as well as to other nuclear 
adaptor proteins, nuclear pore components, 
histone-modifying enzymes and regulators 
of transcription – in some cases regulating 
their recruitment to chromatin. 
Specifically, Ambra1 forms complexes 
with Akap8, Brg1 as well as Atf2 and is 
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responsible for the recruitment of Akap8, 
Bgr1, the Mediator complex component 
Cdk9 as well as p-Atf2 T71 to chromatin. 
Both Ambra1 and its binding protein 
Akap8 regulate the binding of 
transcriptional proteins to chromatin, 
especially p-Atf2 T71, and proteins that 
modulate histone modifications. The 
binding of Atf2/p-Atf2 T71 to chromatin is 
most likely regulated by the Ambra1-
interacting protein Cdk9. Therefore, 
Ambra1 acts as a scaffold protein in the 
nucleus, recruiting transcriptional 
regulators to chromatin. This creates an 
Ambra1-dependent nuclear microdomain 
that regulates gene expression. 
 
RESULTS 
Ambra1 localises to the nucleus 
Here we show that Ambra1 not only locates 
at focal adhesions and in intracellular 
autophagic puncta in SCC cells, but also in 
the nucleus (Figure 1A). Staining with only 
secondary antibodies (anti-rabbit 488 and 
anti-mouse 594) ruled out unspecific false-
positive nuclear staining (Figure S1A). To 
confirm Ambra1 was nuclear 
biochemically, and in order to investigate 
whether this localisation was dependent on 
FAK, fractions of SCC FAK -/- cells and 
the same cells re-expressing wild-type 
FAK to similar levels as parental SCC cells 
(FAK-WT) were isolated and subjected to 
Western blotting (Figure 1B) (15,16).  
Biochemical nuclear isolations were 
checked by blotting with anti-GAPDH, 
anti-Lamin A/C and anti-H4. In the nuclear 
fractions of these SCC cells, we could 
detect Ambra1 as well as FAK, the latter in 
line with our previous reports (17,18). The 
nuclear localisation of Ambra1 was not 
dependent on FAK, as nuclear Ambra1 was 
present at indistinguishable levels in 
nuclear fractions from both FAK -/-  and 
FAK-WT SCC cells and the same cells re-
expressing wild-type FAK to similar levels 
as parental SCC cells (FAK-WT) (15,16). 
In more highly purified cellular fractions of 
SCC FAK-WT and -/- cell lysates, 
extracting cytosolic (C), perinuclear (PN) 
and nuclear (N) fractions (supporting text 
and Figure S1B), Ambra1 was present at 
comparable levels in the cytosolic and 
nuclear fractions, and at even higher levels 
in the perinuclear fraction. Fraction purities 
were confirmed by blotting respective 
fractions with anti-GM130, anti-PDI, anti-
Lamin A/C and anti-GAPDH (Figure S1B). 
Ambra1 could also be detected in the 
nucleus of a human SCC cell line (Figure 
S1C). Furthermore, in contrast to FAK, 
Ambra1 was also detected in nuclear 
extracts from primary mouse keratinocytes 
(Figure S1D) (18). 
Nuclear Ambra1 binds proteins involved 
in transcription 
Next we investigated the nature of protein 
binding partners of Ambra1 in the nucleus. 
Highly purified nuclear extracts of SCC 
FAK-WT and -/- cells were obtained by 
sucrose gradient centrifugation and used 
for Ambra1 immunoprecipitations (anti-
rabbit IgG served as a negative control), 
and specific nuclear binding proteins were 
determined by quantitative label-free mass 
spectrometry (see Materials and Methods) 
(Table S1). In total, 456 Ambra1-
interacting proteins were identified, 
amongst which were several proteins that 
form part of the nuclear pore complex 
(interaction network shown in Figure 1C; 
Table S2). Indeed, we had previously 
observed that the nuclear pore protein Tpr 
was an Ambra1-interacting protein using 
whole cell lysates (4) – together implying 
that Ambra1 was associated with nuclear 
pore proteins either during entry into the 
nucleus or as part of its nuclear functions. 
Gene ontology enrichment analysis of 
biological processes attributed to proteins 
that bind Ambra1 in nuclear fractions 
revealed transcription, mRNA processing, 
histone modification as well as chromatin 
modification and remodelling as the most 
highly over-represented categories (Figure 
S2A). As a result of these analyses, we 
filtered all identified Ambra1-binding 
proteins for Ambra1 interactors likely to be 
involved in the regulation of transcription 
and used these hits to build a protein 
interaction network based on known direct 
physical interactions (Figure 1D and Table 
S2). Amongst these were several 
components of the Mediator complex, a 
multiprotein complex that functions as a 
transcriptional coactivator for RNA 
Polymerase II (highlighted in light red in 
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Figure 1D) (19,20). Also present were 
several components of the SWI/SNF 
(SWItch/Sucrose Non-Fermentable) 
nucleosome remodelling complex that 
allows transcription factor binding by 
‘opening up’ chromatin structure, e.g. the 
catalytic subunit SMARCA4 (Brg1), which 
allows ATP-dependent chromatin 
remodelling (represented in blue in Figure 
1D) (21-23). Nuclear Ambra1 was also 
found to interact with several members of 
the cAMP-dependent AP-1 complex, 
including c-Jun, Fosl2, Atf2 (a member of 
the CREB (cAMP response element 
binding) family of leucine zipper proteins) 
and Atf7, which also binds to nuclear FAK 
(respresented in green in Figure 1D) 
(18,24). As cAMP-regulated transcription 
factors were amongst nuclear Ambra1-
binding proteins, we also noted that nuclear 
Ambra1 binds to Akap8 (A kinase anchor 
protein 8, also known as Akap95), a 
scaffold that targets PKA to cAMP-
responsive elements in gene promoters, and 
which is linked to chromatin status and 
retention of p90 S6K in the nucleus (25-
28). Interestingly, both Atf2 and Akap8 
were also identified by proteomics as 
Ambra1-binding proteins using whole cell 
lysates in our previous experiments (4).  
We next selected a number of proteins 
identified by mass spectrometric analyses, 
i.e. Nup153, Akap8, Brg1, Atf2, and the 
RNA polymerase II Rpb1 (all highlighted 
with red borders in Figure 1, C and D) and 
confirmed their binding to Ambra1 in the 
nucleus by co-immunoprecipitation in 
nuclear fractions (Figure 2, A–E; by 
contrast, we show an example of a nuclear 
protein, PARP, that does not bind Ambra1 
in co-immunoprecipitation experiments in 
Figure S2B). One question we had, given 
our previously reported co-functioning of 
Ambra1 and FAK in the cytoplasm, was 
whether or not FAK may be regulating the 
nuclear translocation of its binding 
partners, such as Ambra1 that also locates 
to the nucleus. We did not find any 
significant difference in the nuclear levels 
of Ambra1 or its interaction with the 
nuclear binding partners examined between 
SCC cells expressing FAK-WT when 
compared to FAK-deficient (-/-) cells; we 
therefore conclude that FAK does not 
regulate the trafficking of Ambra1 to the 
nucleus or Ambra1 interactions there. 
Therefore, in future experiments, we have 
generally only presented data from SCC 
cells expressing FAK-WT. 
Loss of Ambra1 causes reduced 
association of interacting partners with 
chromatin 
Since Ambra1 has predominantly been 
defined as a scaffold protein involved in 
intracellular trafficking/autophagy thus far, 
we hypothesized that Ambra1 might also 
serve as a scaffold protein in the nucleus. 
Using efficient siRNA pool-mediated 
depletion that we have used previously (4), 
we found that reducing Ambra1 levels only 
modestly altered levels of its binding 
proteins in the nucleus (Brg1, Cdk9 and p-
Atf2 T71) (Figure 3, A and B). We next 
isolated chromatin from SCC FAK-WT 
cells after Ambra1 depletion and probed for 
FAK, Brg1, Akap8, Atf2 and its 
phosphorylated (and activated) form p-Atf2 
T71 (Figure 3, C and D). Reduced 
expression of Ambra1 suppressed the 
binding of FAK, Brg1, Akap8 and p-Atf2 
(but not visibly total Atf2) to chromatin to 
a greater or lesser extent. This suggests that, 
as well as Ambra1-mediated chromatin 
recruitment, there are likely other routes by 
which binding partners are recruited to 
chromatin since their recruitment is 
reduced, but not ablated, upon Ambra1 
loss. In these analyses, we also included the 
Cdk8 and Cdk9 components of the 
Mediator complex that modulates RNA 
polymerase II-mediated transcription (29-
31). These were included because they 
were: (1) identified as binding to Ambra1 
in mass spectrometry experiments 
(highlighted with a red border (for Cdk8) in 
Figure 1D; Cdk9 was inferred from a single 
peptide identification, Figure S2C; Table 
S2), and (2) predicted to be enzymes with 
the potential to phosphorylate Atf2 at 
residue T71 on chromatin, which we 
observed in the presence of Ambra1 
(Figure 3; predictions via the Biocuckoo 
phosphorylation prediction site: Cdk8 
(score 40.329; cut-off 29.727), Cdk9 (score 
7.393; cut-off 2.931)). In keeping with 
other Ambra1-binding proteins studied 
here, we found that Cdk9, but not Cdk8, 
binding to chromatin was reduced upon 
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depletion of Ambra1 (Figure 3, C and D). 
In this regard, Cdk9 has been reported to 
bind another SWI/SNF complex 
component, SMARCB1, which has also 
been identified as a nuclear Ambra1 
binding protein (32), implying there are 
likely other components of Ambra1 
complexes that link to chromatin 
remodelling. Taken together, our data 
imply that Ambra1 forms complexes in the 
nucleus with other protein scaffolds, such 
as the PKA scaffold Akap8, chromatin 
modifiers and transcription factors, 
including Atf2.    
Akap8 also regulates the level of p-Atf2 
at chromatin 
Ambra1 binds the PKA scaffold Akap8 and 
is required for its optimal binding to 
chromatin. Upon depletion of Akap8 by 
pooled siRNA, we found that whilst neither 
Ambra1 nor FAK binding to chromatin was 
affected, showing it was downstream of 
FAK/Ambra1, the level of p-Atf2 T71 
associated with chromatin was reduced 
(Figure 4, A and B). This implies a model 
(Figure 4E) whereby Ambra1 is upstream 
of recruitment of Akap8 to chromatin, and 
Akap8, in turn, is required for optimal 
chromatin association of active p-Atf2 that 
is also Ambra1-dependent. Total Atf2 
recruitment was not reduced by depletion 
of Akap8, suggesting that a specific 
function of Akap8 may be to recruit the 
enzyme that phosphorylates Atf2 at 
chromatin. We noted that the activity of 
Atf2 is proposed to be regulated by 
phosphorylation at several residues, 
including T71, by kinases such as ERK, 
JNK, p38 and PLK3, promoting Atf2 
heterodimerisation and increased 
transcription and histone acetyl transferase 
(HAT) activity (24,33-39). However, using 
inhibitors of the kinases proposed above to 
phosphorylate Atf2 on T71, we did not find 
evidence for an obvious key role for any of 
these in regulating Atf2 phosphorylation at 
chromatin in SCC cells used here (not 
shown). Therefore, we examined the 
Mediator complex kinases Cdk8 and Cdk9, 
which, as mentioned previously according 
to the Biocuckoo phosphorylation 
prediction site, may potentially 
phosphorylate Atf2 at T71. We therefore 
depleted Cdk8 and Cdk9 in SCC FAK-WT 
cells and prepared nuclear and chromatin 
fractions to probe for p-Atf2 T71. We 
found that depletion of Cdk9 resulted in 
reduced chromatin-associated p-Atf2 T71 
(Figure 4, C and D) that is also Ambra1- 
and Akap8-dependent; however, in this 
case, total Atf2 recruited to chromatin was 
also reduced. These findings imply that the 
Mediator complex component Cdk9, which 
binds to Ambra1 in the nucleus, controls 
recruitment of Atf2 to chromatin 
downstream of Ambra1 and also Atf2 
phosphorylation/activation.   
Thus, Ambra1 and Akap8, which form a 
complex in the nucleus of SCC cells, both 
contribute to the recruitment of active Atf2 
(p-Atf2 T71) to chromatin, likely, at least 
in part, via the Mediator complex 
component Cdk9 downstream (see model 
in Figure 4E). Therefore, an obvious 
question that follows is whether Ambra1, 
Akap8 and Atf2 co-regulate the expression 
of a sub-set of genes. 
Ambra1, Akap8, CDK9 and Atf2 co-
regulate a sub-set of genes 
The data presented to this point showed that 
Ambra1 localises to the nucleus, associates 
with chromatin and interacts with nuclear 
proteins that regulate transcription. Both 
Ambra1 and its binding partner Akap8 
recruit transcription factors, such as the 
active form of Atf2, p-Atf2 T71, which is 
proposed to result in histone modifications 
and altered chromatin accessibility, leading 
to transcriptional changes (40). To address 
whether there were genes whose 
transcription was co-regulated by Ambra1, 
Akap8 and Atf2, SCC FAK-WT cells were 
transfected with siControl, siAmbra1, 
siAkap8 or siAtf2 siRNA. A sub-set of 
genes whose expression was changed by all 
three protein depletions was identified 
using the nCounter PanCancer Pathways 
Panel. In total, we identified 94 genes that 
were significantly (p < 0.05) at least 2-fold 
up- or downregulated compared to control 
siRNA (Figure 5, A and B, and Figure S3, 
A–F). Ambra1, Atf2 or Akap8 depletion 
significantly altered the expression of 18 
genes from this panel (Figure 5, A and B). 
In order to validate the gene expression 
changes, we performed qRT-PCR for the 
co-regulated genes Angpt1, Tgfb2, Tgfb3, 
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Itga8 and Itgb7 (Figure 5, D and E). For 
Angpt1, Tgfb2, Tgfb3 and Itga8, we 
confirmed the downregulation upon siRNA 
transfection (Figure 5E), whilst 
upregulation of Itgb7 was also confirmed 
(Figure 5E). In addition, pathway analysis 
of Ambra1-, Akap8- and Atf2-regulated 
genes revealed the top enriched signalling 
pathway gene sets ‘PI3K-Akt signalling 
pathway’, ‘pathways in cancer’, ‘focal 
adhesion’ and ‘MAPK signalling pathway’ 
were in common (Figure 5C; for full list, 
see Figure S4), strongly suggesting an 
overlap in the functions of the genes 
regulated by Ambra1, Akap8 and Atf2 
complexes. 
Since we found the nuclear Ambra1-
binding Mediator complex protein Cdk9 to 
be part of the regulation of p-Atf2 at 
chromatin in SCC cells (Figure 4, C and D), 
we next addressed whether Cdk9 was also 
implicated in the transcriptional regulation 
of the above co-regulated genes. Depletion 
of Cdk9 by siRNA resulted in broadly 
similar gene expression changes to that 
observed upon depletion of Ambra1, 
Akap8 or Atf2, e.g. expression of Angpt1, 
Tgfb2, Tgfb3 and Itga8 was reduced 
(Figure 5F), whilst Itgb7 was increased in 
qualitative agreement with the effects of 
depleting Ambra1, Akap8 or Atf2 (Figure 
5F), suggesting that Ambra1, Akap8, Atf2 
and Cdk9 are likely to bind to, and regulate, 
these same gene promoters.  
Taken together, these results imply that 
Ambra1, Akap8, Atf2 and most likely also 
Cdk9 are in the same chromatin complexes, 
likely at the promoters of co-regulated 
genes described above, and potentially 
many more not represented in the mouse 
nCounter PanCancer Pathways Panel used 
here. The presence of chromatin modifiers 
in the nuclear Ambra1 interactome, 
validated in the case of Brg1 (Figures 1 and 
2C), suggested the intriguing possibility 
that the novel transcriptional regulatory 
pathway we describe is, at least in part, 
regulated by chromatin accessibility. In 
keeping with this, the functioning of Atf2, 
which is phosphorylated at T71 
downstream of Ambra1 and Akap8, is 
known to promote HAT activity and 
transcription (35,38). 
Ambra1 and Akap8 regulate histone 
modifications 
Functional interaction network analysis of 
nuclear Ambra1 binding partners identified 
by mass spectrometry revealed several 
components of histone modification 
complexes, including histone acetylation 
complexes NSL (non-specific lethal 
complex), NuA4 (nucleosome 
acetyltransferase of H4) and PCAF 
(p300/CBP-associated factor), as well as 
the histone methylation complex 
MLL1/MLL (mixed-lineage leukemia 1) 
(Figure 6A). Further, gene ontology 
enrichment analysis of biological processes 
attributed to nuclear Ambra1 interactors 
identified covalent chromatin and histone 
modifications as well as chromatin 
remodelling as over-represented categories 
(Figure S2). In addition, Akap8 has been 
reported to bind to Dpy30, a core subunit of 
H3K4 histone methyltransferases (41). 
Therefore, we next addressed whether 
Ambra1 and Akap8 influence histone 
modifications by transfecting SCC FAK-
WT and -/- cells with siControl, siAmbra1 
(Figure 6, B and C) or siAkap8 (Figure 6, 
D and E) siRNA and examined the histone 
modifications H3K4me2, H3Kme3 as well 
as H3K27Ac by Western blotting. Tri-
methylation of lysine-4 and acetylation of 
lysine-27 on histone 3 are generally 
regarded as positive indicators of 
transcriptional activation, promoting gene 
expression (42-45). Depletion of Ambra1 
or Akap8 reduced both di- and tri-
methylation of H3K4 as well as acetylation 
of H3K27 (irrespective of whether FAK 
was present or not). This indicates that both 
Ambra1 and Akap8 can influence histone 
modifications, likely as a result of 
interacting histone-modifying enzymes, 
which could result in chromatin 
remodelling and altered accessibility of 
transcription factors.  
 
DISCUSSION 
Here we describe a completely novel 
transcriptional signalling pathway 
controlled by the scaffold protein Ambra1 
in the nucleus. Like Ambra1, other proteins 
involved in autophagy have been reported 
in the nucleus, e.g. LC3B binds to Lamin 
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B1, mediating the degradation of the 
nuclear lamina and Beclin 1, promoting 
autophagy-independent DNA damage 
repair (46,47). No typical nuclear 
localisation sequence is evident for 
Ambra1, and hence the mechanism of 
nuclear translocation is unknown; however, 
as nuclear Ambra1 interacts with 
components of nuclear pore complexes and 
importins (Figure 1C), it is perhaps likely 
that nuclear import of Ambra1 occurs via 
binding to these in some way. Nuclear 
Ambra1 interacts with chromatin modifiers 
and transcriptional regulators in the 
nucleus, including those also identified as 
proteins that bind to FAK and IL33, e.g. 
SMARCC1, Ruvbl1 and Ruvbl2 (17), 
suggesting there may be a link between 
Ambra1 and FAK functions in the nucleus 
as well as in the cytoplasm (4).  In this 
regard, we did find that the proteins 
associate in the nucleus and that depletion 
of Ambra1 leads to reduced FAK 
recruitment to chromatin. 
The PKA-scaffold Akap8, which binds to 
Ambra1 in the nucleus, has itself 
previously been strongly linked to histone 
modifications and chromatin changes. 
Indeed, by interacting with the MLL1/MLL 
complex via Dpy30, Akap8 regulates 
histone H3K4 methyltransferase 
complexes and binds to the nuclear matrix, 
nucleoporin component Tpr as well as 
chromatin; in turn, this contributes to 
chromosome condensation and 
transcription, effects that are important for 
the mitotic checkpoint (41,48-51). Akap8 
also binds the histone deacetylase HDAC3 
and influences mitosis (52). Therefore, 
existing studies had already suggested a 
scaffolding function for Akap8 in assembly 
of chromatin modification complexes. 
Akap8 dissociates from chromatin and the 
nuclear matrix as a result of nuclear 
tyrosine phosphorylation, and it may have 
a role in regulation of chromatin structural 
changes (53). Finally, a recent study 
confirmed the scaffold function of Akap8 
in organising nuclear microdomains, 
thereby controlling local cAMP for nuclear 
PKA regulation (54) – although it is not 
clear whether this is a chromatin-associated 
function of Akap8. 
Nuclear envelope and nuclear pore 
components, like Nup153, associate with 
chromatin and regulate genome 
organisation and gene expression via 
nuclear pore complexes, acting as scaffold 
platforms to allow the assembly and 
recruitment of transcription factors to the 
nuclear periphery (55,56). Therefore, 
Ambra1 might serve as a molecular 
scaffold that links chromatin to the nuclear 
pore complex, allowing active transcription 
factor binding (such as p-Atf2 T71) and 
resulting gene expression. The most likely 
explanation for our data is that Atf2 is 
phosphorylated by a kinase associated with 
chromatin. Therefore, we examined nuclear 
kinases interacting with Ambra1, e.g. 
Cdk9. However, we could not detect 
decreased Atf2 phosphorylation upon Cdk9 
knockdown. We note that Cdk9 is also 
present in additional complexes besides the 
Mediator complex, and therefore it is 
possible that the effect of Cdk9 knockdown 
on the recruitment of p-Atf2 is independent 
of the Mediator complex. When we looked 
at potential Atf2-binding sequences in the 
genes that were altered after depletion of 
Ambra1, Akap8 and Atf2, we found that 
(according to 
www.natural.salk.edu/CREB) Tgfb2 and 
Tgfb3 both have CRE_TATA boxes that 
might serve as Atf2 binding sites. 
Moreover, it is likely that some of the 
cancer-associated functions of Ambra1 in 
SCC cells (such as cancer cell invasion) are 
associated with the nuclear transcription 
signalling effects we report here, e.g. on 
TGFβ isoforms as well as its trafficking 
effects that we reported previously (4). 
Taken together, our data lead us to propose 
the following model (depicted in Figure 7). 
Ambra1 was already known to localise to 
autophagosomes in the cytoplasm and to 
focal adhesions, where it regulates the 
removal of ‘untethered’ tyrosine kinases 
via an autophagy mechanism (2,4). We 
now show that Ambra1 also interacts with 
nuclear pore proteins, and locates to the 
nucleus, where it is part of a complex 
network of inter-linked chromatin 
modifiers and transcriptional regulators, 
including a set of interacting proteins 
whose recruitment to chromatin is 
influenced by Ambra1. This includes the 
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PKA-scaffold Akap8, the Mediator 
complex component Cdk9 and the 
transcription factor Atf2 in its active form. 
Moreover, Ambra1, Akap8, Cdk9 and Atf2 
co-regulate the expression of a sub-set of 
genes. Both Ambra1 and Akap8 influence 
cellular histone modification that could 
contribute to their transcriptional effects. 
Therefore, we have uncovered a completely 
novel function for the autophagy and 
trafficking protein Ambra1, which acts as a 
nuclear scaffold to recruit other scaffold 
proteins, chromatin modifiers and 
transcriptional regulators to elicit gene 
expression changes via Atf2. A similar 
scaffolding mechanism creating nuclear 
‘transcription signalling hubs’ has been 
described for FAK, controlling Ccl5, Il33, 
Tgfb2 and Igfbp3 transcription as well as 
for mAKAPβ, which creates nuclear 
‘signalosomes’ and binds the 
transcriptional regulators NFAT, MEF2 
and HIF1α (18,57,58).  
 
MATERIALS AND METHODS 
Antibodies 
Antibodies used were as follows: anti-
Paxillin and anti-GM130 antibodies (BD 
Transduction Laboratories, New Jersey, 
USA), anti-Akap8 and anti-Nup153 
(Abcam, Cambridge, UK), anti-FAK, anti-
PDI, anti-p-Atf2 T71, anti-Atf2, anti-Brg1, 
anti-Rpb1, anti-Cdk8, anti-Cdk9, anti-
Histone H4, anti-H3K4me2, anti-
H3K4me3, anti-H3K27Ac, anti-Histone 
H3, anti-Lamin A/C and anti-GAPDH (Cell 
Signaling Technologies, Danvers, MA, 
USA), as well as anti-Ambra1 antibody 
(Millipore, Billerica, MA, USA). Anti-
rabbit or mouse peroxidase-conjugated 
secondary antibodies were purchased from 
Cell Signaling Technologies.  
Cell culture 
FAK-deficient SCC cell lines were 
generated as described previously (16). 
SCC cells were maintained in Glasgow 
MEM containing 10% FCS, 2 mM L-
glutamine, non-essential amino acids, 
sodium pyruvate and MEM vitamins at 
37°C, 5% CO2. SCC FAK-WT cells were 
maintained in 1 mg/ml hygromycin B.  
siRNA 
FAK-WT or FAK -/- SCC cells were 
transiently transfected using HiPerFect 
(Qiagen, Manchester, UK), according to 
manufacturer’s protocol, with a final 
concentration of 80 or 100 nM siRNA, 
respectively (Table S3). Cells were 
analyzed at 48 h post transfection.  
Whole cell lysates 
Cells were washed twice in ice-cold PBS 
and then lysed in RIPA buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1% Triton X-
100, 0.1% SDS and 0.5% sodium 
deoxycholate) supplemented with 
PhosSTOP and cOmplete Ultra 
phosphatase and protease inhibitor 
cocktails (Roche, Welwyn Garden City, 
UK) and cleared by centrifugation. 
Nuclear fractionation 
Cells were washed twice in ice-cold PBS 
and then lysed in DET buffer (150 mM 
NaCl, 25 mM Hepes, pH 7.5, 1 mM β-
mercaptoethanol, 0.2 mM CaCl2, 0.5 mM 
MgCl2, 0.5% NP-40) supplemented with 
PhosSTOP and cOmplete Ultra 
phosphatase and protease inhibitor 
cocktails. Lysates were incubated on ice for 
10 minutes and centrifuged. The resulting 
pellets were washed twice in DET buffer, 
resuspended in RIPA buffer and cleared by 
centrifugation. 
For mass spectrometry, nuclear lysates 
were prepared using a Nuclei PURE Prep 
isolation kit (Sigma, Gillingham, UK). 
Chromatin isolation 
The protocol was adapted from McAndrew 
et al. (59). All buffers were supplemented 
with PhosSTOP and cOmplete Ultra 
phosphatase and protease inhibitor 
cocktails. Briefly, cells were washed twice 
in ice-cold PBS, lysed in extraction buffer 
(10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 
mM MgCl2, 0.34 M sucrose, 10% glycerol, 
0.2% NP-40) and centrifuged for 5 minutes 
at 6500 g. Nuclear pellets were washed in 
extraction buffer without NP-40 and 
centrifuged for 5 minutes at 6500 g. Pellets 
were resuspended in low-salt buffer (10 
mM Hepes, pH 7.9, 3 mM EDTA, 0.2 mM 
EGTA) and incubated for 30 minutes at 4 
°C with rotation, before centrifugation for 
5 minutes at 6500 g. Pellets were 
resuspended in high-salt buffer (50 mM 
Tris-HCl, pH 8.0, 2.5 M NaCl, 0.05%  NP-
40) and incubated for 30 minutes at 4 °C 
with rotation. Supernatants containing 
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chromatin fractions were cleared by 
centrifugation. Proteins were precipitated 
by adding TCA to a final volume of 10% 
and incubating on ice for 15 minutes. 
Precipitated proteins were pelleted by 
centrifugation, washed twice with ice-cold 
acetone and then resuspended in 2× sample 
buffer prior to analysis by Western blotting. 
Immunoprecipitation 
Protein concentration was calculated using 
a BCA protein assay kit (Thermo Fisher 
Scientific, Loughborough, UK). For 
analysis by Western blotting, 1 mg lysates 
were incubated with 2 μg of unconjugated 
antibodies at 4°C overnight with agitation. 
Unconjugated antibody samples were 
incubated with 10 μl of Protein A agarose 
for 1 h at 4°C. Beads were washed three 
times in lysis buffer and once in 0.6 M LiCl, 
resuspended in 20 μl 2× sample buffer (130 
mM Tris, pH 6.8, 20% glycerol, 5% SDS, 
8% β-mercaptoethanol, bromophenol blue) 
and heated for 5 minutes at 95°C. Samples 
were then subjected to SDS-PAGE analysis 
as described elsewhere (4). 
For mass spectrometry, Ambra1 was 
immunoprecipitated from 2 mg nuclear 
lysates of SCC FAK-WT and -/- cells 
(samples in triplicates) using a KingFisher 
Duo liquid handling station (Thermo Fisher 
Scientific). Nuclear lysates were incubated 
with 2 μg of antibody and 5 µl Protein G 
Mag Sepharose (GE Healthcare) for 2 h at 
4°C. Beads were washed twice in lysis 
buffer and three time in TBS and then 
processed by proteolytic digestion. 
Proteolytic digestion 
For mass spectrometry, 
immunoprecipitated proteins were digested 
using 5 μg/ml trypsin in 2 M urea, 50 mM 
Tris-HCl, pH 7.5, as reported previously 
(60). Digestion was performed for 30 min 
at 27°C. After the initial digestion, the 
beads were removed using a KingFisher 
Duo and the supernatants were left to 
continue to digest at 37°C for 8 h. After 
digestion, samples were incubated with 50 
mg/ml iodoacetamide 30 min in the dark. 
Samples were treated with 1 μl 
trifluoroacetic acid (TFA) to stop the 
digestion and then desalted using C18 
StageTips. Briefly, the tips were prepared 
by placing a small disc of 3M Empore 
solid-phase extraction material (Sigma-
Aldrich) in an ordinary 200-μl-capacity 
pipette tip, preparing a single tip for each 
sample. Tips were activated with 80% 
acetonitrile, 0.1% TFA buffer and washed 
with 0.1% TFA. Samples (100 μl) were 
added to each column and washed twice 
with 0.1% TFA. Liquid was passed through 
the pipette tip manually with the aid of a 
syringe or with a light centrifugation step. 
Peptides were then eluted using 80% 
acetonitrile, 0.1% TFA. Samples were 
evaporated in a SpeedVac vacuum 
concentrator (Thermo Fisher Scientific), 
re-suspended in 12 μl 0.1% TFA buffer and 
analysed by mass spectrometry. 
Mass spectrometric data acquisition 
Tryptic peptides were analysed on a Q 
Exactive Plus Hybrid Quadrupole-Orbitrap 
mass spectrometer connected to an 
UltiMate Ultra3000 chromatography 
system (both Thermo Fisher Scientific) 
incorporating an autosampler. Peptides (5 
μl), for each sample, were loaded on a 
homemade column (250-mm length, 75-
μm inside diameter) packed with 1.8 μm 
UChrom C18 (nanoLCMS Solutions)  and 
separated by an increasing acetonitrile 
gradient, using a 40-min reverse-phase 
gradient (from 3%–32% acetonitrile) at a 
flow rate of 250 nl/min. The mass 
spectrometer was operated in positive ion 
mode with a capillary temperature of 
220°C, with a potential of 2000 V applied 
to the column. Data were acquired with the 
mass spectrometer operating in automatic 
data-dependent switching mode, selecting 
the 12 most intense ions prior to tandem 
mass spectrometric analysis. All spectra 
were acquired with 1 microscan and 
without lockmass. 
Mass spectrometric data analysis 
Label-free quantitative analysis of mass 
spectrometric data was performed using 
MaxQuant (version 1.5.7.4). All the 
experimental conditions (Ambra1 and IgG 
control immunoprecipitations from SCC 
FAK-WT and -/- cells) were analysed in 
biological triplicate. Each raw data file was 
considered as separate in the experimental 
design; the replicates of each experimental 
condition were grouped for the subsequent 
statistical analysis. Raw data files were 
searched against the mouse UniProtKB 
database (version 2017_05; 86,453 entries) 
and a common contaminants database 
using the Andromeda search engine 
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(packaged with MaxQuant, version 
1.5.7.4). A mass accuracy of 4.5 ppm was 
applied, and a false discovery rate (FDR) of 
1%, applying a target-decoy search strategy 
using MaxQuant, was set at both the 
peptide and protein levels. Enzyme 
specificity was set as C-terminal to arginine 
and lysine, except when followed by 
proline, and a maximum of two missed 
cleavages were allowed in the database 
search. Cysteine carbamidomethylation 
was specified as a fixed modification; 
methionine oxidation and acetylation of 
protein N-termini were specified as 
variable modifications. Minimum peptide 
length was seven amino acids, and at least 
one peptide ratio was required for label-free 
quantification. Peptide identifications in 
one or more sample runs not identified in 
other samples were matched and 
transferred between runs (0.7-min time 
window). Proteins matching to the reversed 
or common contaminants databases were 
omitted, and ribosomal proteins were 
omitted as putative contaminants. Missing 
values were replaced by a constant (1), and 
significant protein interactors were 
determined based on average ratio (fold 
change over IgG control) and Student’s t-
test. Interaction network analysis was 
performed using Cytoscape.  
Immunofluorescence microscopy and 
image analysis 
Cells were fixed, stained and imaged as 
described in Schoenherr et al. (4).  
qRT-PCR 
RNA from cells was isolated using the 
RNeasy Mini Kit (Qiagen, Manchester, 
UK). 500 ng total RNA were reverse-
transcribed using the SuperScript First-
Strand cDNA synthesis kit (Life 
Technology, Paisley, UK). For the PCR 
amplification in a Step One Plus real-time 
PCR system (Life Technology, Paisley, 
UK), 25 ng cDNA were used in a total 
reaction mix of 20 μl containing 10 μl Sensi 
Fast SYBR Green Hi-Rox (Bioline, 
London, UK) as well as 400 nM forward 
and reverse primers (Table S4). Gapdh was 
used to control for differences in cDNA 
input. Relative expression was calculated 
according to the ΔΔCt quantification 
method. Each sample within an experiment 
was analysed in triplicate and the 
experiment was carried out three times.  
nCounter gene expression analysis 
SCC FAK-WT cells were transfected with 
siControl, siAmbra1, siAkap8 and siAtf2 
siRNA. RNA from cells was isolated 48 h 
post transfection using the RNeasy Mini 
Kit (Qiagen, Manchester, UK) and diluted 
to 20 ng/μl. Samples (in triplicates) were 
subjected to gene expression analysis using 
the mouse nCounter PanCancer Pathways 
panel (Nanostring, Amersham, UK). 
Analysis was performed using nSolver 
analysis software (Nanostring). The cut-off 
point of statistically significant relative 
changes (siRNA/siControl, p < 0.05) was 
set to 2-fold. 
Statistical tests 
For all experiments shown, n = 3–5. Error 
bars for the graphs show s.d. Student’s t-




The mass spectrometry-based proteomics 
data have been deposited to the 
ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.
org/) via the PRIDE partner repository with 
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Figure 1. Nuclear Ambra1 binds chromatin modifiers and transcriptional regulators. (A) 
Representative immunofluorescence images of SCC FAK-WT and -/- cells which were grown 
on glass coverslips for 24 h, fixed and stained with anti-Ambra1, anti-Paxillin and DAPI. Scale 
bars, 20 μm. (B) Whole cell and nuclear lysates of SCC FAK-WT and -/- cells were subjected 
to Western blot analysis with anti-Ambra1 and anti-FAK. Anti-GAPDH, anti-Lamin A/C and 
anti-H4 served as controls for the purity of the nuclear extracts as well as loading controls. (C, 
D) Interaction network analysis of nuclear Ambra1-binding proteins in SCC FAK-WT and -/- 
cells associated with the nuclear pore complex (C) and being involved in transcription (D), as 
determined by gene ontology enrichment analysis of biological processes. Hits were filtered 
for statistically significant (p < 0.05) 2-fold enrichment over IgG control and used to build a 
protein interaction network based on direct physical interactions (grey lines). Components of 
various complexes involved in transcription are highlighted: SWI/SNF complex (blue nodes), 
cAMP-regulated transcription factor (green nodes) and Mediator complex (light red nodes). 
Ambra1-interacting proteins selected for further investigation are highlighted with a red border. 
Figure 2. Nuclear Ambra1 binding to mass spectrometry-identified interaction partners. 
Ambra1 was immunoprecipitated from whole cell and nuclear lysates of SCC FAK-WT and -
/- cells using anti-Ambra1, followed by Western blot analysis with anti-Ambra1 and anti-
Nup153 (A), anti-Akap8 (B), anti-Brg1 (C), anti-Atf2 (D) and anti-Rpb1 (E). Anti-Lamin A/C 
and anti-GAPDH were used as a control for the purity of the nuclear lysates as well as a loading 
control. 
Figure 3. Loss of Ambra1 leads to reduced association of interacting proteins with 
chromatin. (A) SCC FAK-WT cells were transfected with siControl and siAmbra1 
(siGENOME pool). After 48 h, whole cell and nuclear lysates were analysed by Western blot 
using anti-Ambra1, anti-FAK, anti-Brg1, anti-Akap8, anti-Cdk8, anti-Cdk9, anti-p-Atf2 T71 
and anti-Atf2. Anti-Lamin A/C and anti-GAPDH were used as controls for the purity of the 
nuclear lysates as well as loading controls. (B) The graph shows relative nuclear protein levels 
normalised to Lamin A/C. Error bars represent s.d. *, p < 0.01; #, p < 0.05. (C) SCC FAK-WT 
cells were transfected with siControl and siAmbra1. After 48 h, whole cell lysates and 
chromatin extracts were analysed by Western blot using anti-Ambra1, anti-FAK, anti-Brg1, 
anti-Akap8, anti-Cdk8, anti-Cdk9, anti-p-Atf2 T71 and anti-Atf2. Anti-Histone H4 served as a 
marker for chromatin as well as a loading control. (D) The graph shows relative chromatin 
protein levels normalised to Histone H4. Error bars represent s.d. *, p < 0.01; #, p < 0.05.  
Figure 4. Depletion of Akap8 and Cdk9 reduce p-Atf2 T71 binding to chromatin. (A) SCC 
FAK-WT cells were transfected with siControl and siAkap8 (siGENOME pool). After 48 h, 
whole cell lysates and chromatin extracts were analysed by Western blot using anti-Ambra1, 
anti-FAK, anti-p-Atf2 T71, anti-Atf2 and anti-Akap8. Anti-Histone H4 served as a marker for 
chromatin as well as a loading control. (B) The graph shows relative chromatin protein levels 
normalised to Histone H4. Error bars represent s.d. *, p < 0.01; #, p < 0.05. (C) SCC FAK-WT 
cells were transfected with siControl, siCdk8 and siCdk9 (siGENOME pool). After 48 h, whole 
cell lysates, nuclear and chromatin extracts were analysed by Western blot using anti-pAtf2 
T71, anti-Atf2, anti-Cdk8 and anti-Cdk9. Anti-Lamin A/C, anti-GAPDH and anti-Histone H4 
served as controls for the purity of nuclear and chromatin extracts as well as loading controls. 
(D) The graph shows relative nuclear or chromatin protein levels normalised to Lamin A/C or 
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Histone H4, respectively. Error bars represent s.d. *, p < 0.01; #, p < 0.05. (E) Hypothesis 
model. In the nucleus of SCC cells, Ambra1 and Akap8 form a complex and contribute to the 
recruitment of active Atf2 (p-Atf2 T71) to chromatin, most likely downstream via the Mediator 
complex component Cdk9. This strongly suggests that Ambra1 might be involved in chromatin 
remodelling and transcription. Further, together with Akap8 and Atf2, it might co-regulate the 
expression of a sub-set of genes.  
Figure 5. Ambra1, Akap8, Cdk9 and Atf2 co-regulate a sub-set of genes. SCC FAK-WT 
cells were transfected with siControl, siAmbra1, siAkap8 and siAtf2 (siGENOME pool). RNA 
was isolated 48 h post transfection and subjected to gene expression analysis using the mouse 
nCounter PanCancer Pathways panel. (A) Venn diagram of significantly altered genes 
compared to siControl (p < 0.05, 2-fold difference compared to siControl). (B) Relative gene 
expression of 18 genes co-regulated by Ambra1, Akap8 and Atf2 knockdown compared to 
siControl. (C) Table of the top five enriched signalling pathway gene sets according to KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathway analysis of Ambra1-, Akap8- and Atf2-
regulated genes. (D) Western blot showing Atf2 knockdown by siRNA in SCC FAK-WT cells. 
Anti-GAPDH served as a loading control. (E, F) Validation of Ambra1, Akap8 and Atf2 
mediated Angpt1, Tgfb2, Tgfb3, Itga8 and Itgb7 expression changes by qRT-PCR using RNA 
isolated 48 h post transfection of SCC FAK-WT cells with siControl, siAmbra1, siAkap8 and 
siAtf2 (E) as well as siControl and siCdk9 (F). Error bars represent s.d. *, p < 0.01; #, p < 0.05.  
Figure 6. Ambra1 or Akap8 depletion decreases histone modifications. (A) Functional 
interaction network analysis of nuclear Ambra1 binding partners identified by mass 
spectrometry were filtered for statistically significant (p < 0.05) 2-fold enrichment over IgG 
control. Components of histone modification complexes were used to build a protein interaction 
network based on direct physical interaction (grey lines). These complexes include histone 
acetylation complexes (NSL, Non-specific lethal; NuA4, nucleosome acetyltransferase of H4; 
PCAF, p300/CBP-associated factor) and a histone methylation complex (MLL1/MLL, mixed-
lineage leukemia 1) (all highlighted by light blue background). (B–E) SCC FAK-WT and -/- 
cells were transfected with siControl and siAmbra1 (B, C) or siControl and siAkap8 (D, E) 
(siGENOME pool). After 48 h, whole cell lysates were subjected to Western blot analysis using 
anti-Ambra1, anti-Akap8, anti-di-H3K4me, anti-tri-H3K4me and anti-H3K27Ac. Anti-
GAPDH and anti-Histone H3 served as loading controls. (C, E) The graphs show relative 
histone modification levels normalised to Histone H3 or protein levels normalised to GAPDH 
upon Ambra1 (C) or Akap8 (E) knockdown. Error bars represent s.d. *, p < 0.01; #, p < 0.05.  
Figure 7. Model depicting Ambra1-dependent transcriptional regulation. In mouse SCC 
cells, Ambra1 is already known to localise to autophagosomes and focal adhesions, where it 
binds FAK and Src and regulates the removal of untethered kinases via autophagy. Ambra1 can 
also interact with nuclear pore components and is translocated into the nucleus most likely via 
nuclear pores and importins. Nuclear Ambra1 is part of a network consisting of chromatin 
modifiers and transcriptional regulators, some of which are recruited to chromatin in an 
Ambra1-mediated manner, including the PKA-scaffold Akap8, Cdk9 and active Atf2 (p-Atf2 
T71). Further, Ambra1, Akap8, Cdk9 and Atf2 co-regulate the expression of a sub-set of genes 
like Angpt1, Tgfb2, Tgfb3, Itga8 and Itgb7. Both Ambra1 and Akap8 influence cellular histone 
modifications, which could contribute to their transcriptional effects. Overall, the autophagy 
protein Ambra1 also acts as a nuclear platform to recruit key scaffolds, chromatin modifiers 




















































































































































Figure 3 Loss of Ambra1 leads to reduced association of interacting proteins with chromatin
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Relative fold transcription (siRNA/siControl)
siAmbra1 siAkap8 siAtf2
Term % Term % Term %
PI3K‐Akt signaling pathway 40.4 Pathways in cancer 36.6 PI3K‐Akt signaling pathway 36.9
Pathways in cancer 38.5 Focal adhesion 34.1 Pathways in cancer 32.3
Focal adhesion 25.0 PI3K‐Akt signaling pathway 34.1 Focal adhesion 21.5
MAPK signaling pathway 21.2MAPK signaling pathway 26.8MAPK signaling pathway 20.0
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Figure 7 Model depicting Ambra1-dependent transcriptional regulation
